ZEAL Share Price Performance
DKK 399.20
-509.80 (-56.08%)
64.4% undervalued intrinsic discount
DKK 1,120.00
Fair Value
Price DKK 399.20
AnalystHighTarget DKK 1,120.00
AnalystConsensusTarget DKK 830.75
Fair ValueDKK 1,120.00
Share PriceDKK 399.20
64.4% undervalued intrinsic discount
ZEAL Community Narratives
AN
Fair Value DKK 1.12k 64.4% undervalued intrinsic discount
Roche Partnership Will Advance Peptide Therapies Amid Obesity Risks
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value DKK 830.75 51.9% undervalued intrinsic discount
Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
Zealand Pharma A/S Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 13, 2025
- Earnings per share (EPS)
- 94.92
- Gross Margin
- 100.06%
- Net Profit Margin
- 73.34%
- Debt/Equity Ratio
- 1.9%
Zealand Pharma A/S Competitors
This week, we’re going to look at the U.S. regulatory changes, how adoption has been trending, and one of the risks with the ETFs. If you want some exposure to Bitcoin, at the end, we’ll show you some different ways you can position your portfolio accordingly.
Continue reading
About ZEAL
- Founded
- 1997
- Employees
- 424
- CEO
- WebsiteView website
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
Danish Market Performance
- 7 Days: 3.4%
- 3 Months: -12.2%
- 1 Year: -39.8%
- Year to Date: -24.9%
Over the last 7 days, the market has risen 3.4%, driven by gains of 7.1% in the Healthcare sector. On the other hand, with a decline of 12%, the Consumer Discretionary sector is lagging behind. In contrast, the market has seen a decline of 40% over the last 12 months. As for the next few years, earnings are expected to grow by 4.8% per annum. Market details ›